BLTE NASDAQ
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
San Diego, CA 92130
US
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Scholl Hendrik Peter | S-Sale | 200 | $163.62 | 2026-10-01 |
| Scholl Hendrik Peter | S-Sale | 24 | $164.64 | 2026-10-01 |
| Scholl Hendrik Peter | S-Sale | 120 | $165.49 | 2026-10-01 |
| Scholl Hendrik Peter | S-Sale | 50 | $166.44 | 2026-10-01 |
| Scholl Hendrik Peter | S-Sale | 78 | $167.59 | 2026-10-01 |